Skip to main content

Table 3 PI-MBS and PGIC ratings at Week 12 in eptinezumab-treated ≥ 75% and ≥ 50–< 75% migraine responders (PROMISE-2; eptinezumab pooled)

From: Patient-reported outcomes, health-related quality of life, and acute medication use in patients with a ≥ 75% response to eptinezumab: subgroup pooled analysis of the PROMISE trials

  PI-MBS PGIC
≥ 50–< 75% ≥ 75% ≥ 50–< 75% ≥ 75%
n 200 208 200 207
Very much improved 33 (16.5%) 87 (41.8%) 40 (20.0%) 75 (36.2%)
Much improved 101 (50.5%) 90 (43.3%) 99 (49.5%) 103 (49.8%)
Minimally improved 46 (23.0%) 21 (10.1%) 40 (20.0%) 16 (7.7%)
No change 14 (7.0%) 5 (2.4%) 17 (8.5%) 10 (4.8%)
Minimally worse 5 (2.5%) 5 (2.4%) 2 (1.0%) 3 (1.4%)
Much worse 1 (0.5%) 0 2 (1.0%) 0
  1. A ≥ 75% or ≥ 50–< 75% migraine responder was defined as a patient who achieved a ≥ 75% or ≥ 50–< 75% reduction in mean monthly migraine days over Weeks 1–12. PGIC, Patient Global Impression of Change; PI-MBS, patient-identified most bothersome symptom